TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12823079
Drug: Imipramine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (100 to 200 mg daily)
Study: 1996743
Drug: Chloroquine (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (weekly for four weeks)
Study: 1996743
Drug: Chloroquine and
Normalized name: chloroquine and proguanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine and No drug (both groups)
Study: 25753207
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g aspirin
Study: 19018783
Drug: Low-dose pioglitazone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pioglitazone (7.5 mg/day; 21/28 days)
Study: 9752892
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 to 10 mg)
Study: 11287711
Drug: Enoxaparin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1.0 mg/kg intravenously (without abciximab)
Study: 11287711
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose enoxaparin 0.75 mg/kg in combination with standard-dose abciximab intravenously during PCI
Study: 9505993
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of valspodar (400 mg as microemulsion soft gelatin capsules)
Study: 7939618
Drug: Lead in
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead in air (PbA) in the administration area: 4.2 micrograms/m3
Study: 29504666
Drug: Weekly phone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly phone call feedback for control group caregivers.
Study: 16449396
Drug: Evidence-based collaborative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based collaborative depression treatment (pharmacotherapy, problem-solving treatment, or both)
Study: 10718681
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 300 mg/day for 3 months
Study: 3944270
Drug: TxB2 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TxB2 infusion at 1.0 ng/kg X min
Study: 30354330
Drug: GIST (Genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIST (Genotype Informed Statin Therapy)
Study: 27289365
Drug: TFMPP (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFMPP (60 mg)
Study: 27289365
Drug: Dexamphetamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamphetamine (20 mg)
Study: 26630992
Drug: Benzylpiperazine (BZP)
Normalized name: cinnamido benzylpiperidinyl ethoxypropylbenzamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzylpiperazine (BZP) (200 mg)
Study: 26630992
Drug: BZP +
Normalized name: Benzylpiperazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZP + TFMPP (100/30 mg)
Study: 25518117
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated by injection of 10 mg of Metoclopramide into the deltoid muscle and gluteus maximus muscle
Study: 14604244
Drug: Standard single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard single prebypass heparin dose (300 IU/kg)
Study: 25725625
Drug: Ephedrine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 1.5 mg kg(‐1) day(‐1) for 28 days
Study: 25725625
Drug: Acute ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute ephedrine (2.5 mg/kg) after 28 days of treatment
Study: 23551710
Drug: Trivalent influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent influenza virus vaccine (TIV) in pregnant women
Study: 30136707
Drug: Clarithromycin tablet
Normalized name: Clarithromycin Tablets
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin tablet at 250 mg once daily for 3 months
Study: 19155592
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g maltodextrin + 7.5 g D-psicose
Study: 16753648
Drug: Not in
Normalized name: Blood group antigen associated with but not included in MNS system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not in treatment (NT)
Study: 10506661
Drug: Experimentally raised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimentally raised anti-osteopontin antibodies
Study: 8932874
Drug: ICI182780 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI182780 6 mg/day (n = 10) for 7 days
Study: 8932874
Drug: Tamoxifen (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (4 x 40 mg on day 1, 20 mg/day thereafter, median 21 days) (n = 8)
Study: 8932874
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no preoperative treatment n = 9, placebo n = 7)
Study: 1411629
Drug: Carboplatin 50
Normalized name: CARBOPLATIN 50MG/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin 50 mg/m2 with 67.2 Gy radiation
Study: 1992531
Drug: Carboplatin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (various doses) with 58.8 Gy radiation
Study: 1992531
Drug: Carboplatin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (various doses) with radiation
Study: 20838741
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once daily in ambulatory patients
Study: 20838741
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once daily in non-ambulatory patients
Study: 18269820
Drug: Primary PCI
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary PCI combined with tirofiban therapy (Tirofiban group, n = 80)
Study: 15386821
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus pioglitazone (15 mg o.d. titrated up to 45 mg)
Study: 15386821
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus gliclazide (80 mg o.d. titrated up to 320 mg)
Study: 11870502
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with sequential subcutaneous IL-2 and IFN-alpha
Study: 26334096
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/kg2 iv)
Study: 26334096
Drug: Gemcitabine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine with Pegintron (1 μg/kg sc)
Study: 26334096
Drug: Gemcitabine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine with Pegintron and p53 SLP vaccine (0.3 mg/peptide, 9 peptides)
Study: 22643801
Drug: Fast-track rehabilitation
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-track rehabilitation (Joint Care®) with group therapy, early mobilization (same day as surgery), and 1:1 physiotherapy (2 h/day)
Study: 17317391
Drug: CVD treatment
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD treatment (calcium channel blockers)
Study: 9362390
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of interferon therapy (IFN), 3-5 MU three times weekly
Study: 9362390
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of observation followed by 6 months of IFN therapy
Study: 24339936
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 80 kVp and contrast media of 270 mgI/ml with iterative reconstruction algorithm
Study: 24339936
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 120 kVp and contrast media of 320 mgI/ml
Study: 20523219
Drug: Chronic aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic aspirin therapy
Study: 20523219
Drug: Chronic antiplatelet
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic antiplatelet therapy (single or dual)
Study: 1692755
Drug: Caffeine 450
Normalized name: HYALURONIC ACID 2250 mg in 45 mL / SHEA BUTTER 1800 mg in 45 mL / COLLAGEN, SOLUBLE, FISH SKIN 2250 mg in 45 mL / RETINOL 405 mg in 45 mL / CAFFEINE 450 mg in 45 mL / SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL 450 mg in 45 mL TOPICAL LIQUID [AOAO Retinol Anti-aging Box Set]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 450 mg
Study: 18458357
Drug: Caffeine 0
Normalized name: caffeine 0.65 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 0 mg
Study: 8882988
Drug: Etoposide 200
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 200 mg/m2/day on days 1‐3 and cisplatin 35 mg/m2/day on days 1‐3 (Phase I)
Study: 8882988
Drug: Etoposide 200
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 200 mg/m2/day on days 1‐3 and cisplatin 35 mg/m2/day on days 1‐3 (Phase II)
Study: 1563057
Drug: Epidural infusions
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusions of fentanyl alone
Study: 3904394
Drug: Metoprolol, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol, 15 mg intravenously, and 50 mg 4 times a day orally (n = 95)
Study: 31746629
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (1-4 µg·kg‐1·min‐1)
Study: 31746629
Drug: Acute hyperoxia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute hyperoxia + low-dose dopamine
Study: 29356932
Drug: Standard cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cold therapy protocol
Study: 22362136
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose images
Study: 1283426
Drug: Fosinopril, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril, a phosphorus-containing ACE inhibitor, administered as a prodrug.
Study: 1283426
Drug: Standard ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ACE inhibitors that require dosage adjustment due to renal insufficiency.
Study: 3929609
Drug: 2 gm
Normalized name: Algiderm 2 gm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 gm solution of cefamandole
Study: 28135975
Drug: Sorghum group
Normalized name: Sorghum
DrugBank: Sorghum (DB17914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorghum group (45g of flaked cereal biscuits daily for 12 weeks)
Study: 28135975
Drug: White wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White wheat group (45g of flaked cereal biscuits daily for 12 weeks)
Study: 10481420
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose in Ringer's acetate solution (2 ml)
Study: 12382386
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine (2 ml)
Study: 10481420
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (2 ml) (Control Group)
Study: 8588396
Drug: L-Dopa 100
Normalized name: L-DOPA 100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Dopa 100 to 200 mg
Study: 1951872
Drug: Chloroquine diphosphate
Normalized name: CHLOROQUINE DIPHOSPHATE, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine diphosphate (500 mg/week)
Study: 1951872
Drug: Proguanil hydrochloride
Normalized name: Proguanil Hydrochloride
DrugBank: Proguanil (DB01131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proguanil hydrochloride (200 mg/day)
Study: 7035578
Drug: Polysaccharide-protein complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide-protein complex vaccine
Study: 15300183
Drug: Oxandrolone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (0.1 mg/kg po bid)
Study: 2655500
Drug: Therapeutic blood
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic blood patch administered to perpendicular group
Study: 2655500
Drug: Therapeutic blood
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic blood patch administered to parallel group
Study: 31201479
Drug: Dronabinol (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (0, 2.5, 5 mg)
Study: 23040652
Drug: G1: 20mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: G1: 20mL L+10mL M
Study: 23040652
Drug: G3: 15mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: G3: 15mL L+15mL M
Study: 23040652
Drug: G2: 10mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: G2: 10mL L+20mL M
Study: 19888533
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (testosterone undecanoate 1,000 mg, intramuscular injections, 5 injections over 40 weeks)
Study: 9872339
Drug: Intravenous rizatriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rizatriptan (0.5-5 mg)
Study: 7523132
Drug: Transurethral catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral catheter therapy for 1 hour (Control)
Study: 7523132
Drug: Transurethral catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral catheter therapy (Control)
Study: 2802836
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant human growth hormone (GH)
Study: 30515674
Drug: palbociclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: palbociclib (125 mg/day [3 weeks on/1 week off]) plus letrozole (2.5 mg daily)
Study: 28455600
Drug: Placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral preoperatively
Study: 18359622
Drug: 0.3% dehydroepiandrosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% dehydroepiandrosterone (DHEA) applied twice daily for 12 months
Study: 12730532
Drug: 3-monthly i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-monthly i.v. ibandronate (2 mg) bolus injections
Study: 12730532
Drug: Oral daily
Normalized name: Summer's Eve Sheer Floral Daily Cloths
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily alfacalcidol (1 micro g)
Study: 2833090
Drug: Lisinopril alone
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril alone (group A)
Study: 2833090
Drug: Lisinopril plus
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril plus hydrochlorothiazide (group B)
Study: 26335224
Drug: 37.5 mg
Normalized name: pemoline 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg daily sunitinib therapy
Study: 22903515
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (400 μg every 6 h)
Study: 25542295
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate 40 mg/mL three‐times weekly (GA40)
Study: 24005315
Drug: GHD patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHD patients with 25(OH)D ≥15 ng/ml
Study: 24005315
Drug: GHD patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHD patients with 25(OH)D <15 ng/ml
Study: 20961422
Drug: 5.83 mg/mL
Normalized name: somatropin 5.83 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.83 mg/mL liquid formulation
Study: 20961422
Drug: 8.0 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.0 mg/mL liquid formulation
Study: 20961422
Drug: Freeze-dried (FD)
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried (FD) formulation
Study: 10994151
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (amlodipine tablet broken into two halves and encapsulated)
Study: 10994151
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (amlodipine tablet broken into two halves and ingested as such)
Study: 29327213
Drug: Adjunctive curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive curcumin (500 to 1500 mg/day)
Study: 29327213
Drug: Adjunctive curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive curcumin
Study: 14655848
Drug: Cognitive‐Behavioral Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐Behavioral Therapy (CBT)
Study: 22374612
Drug: Perfusion group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion group (DXM 2.5 mg/0.5 ml perfused transtympanically for 1 h twice a day for 7 days, total 35.0 mg)
Study: 22374612
Drug: Drip group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drip group (DXM 2.5 mg/0.5 ml dripped via a ventilation tube once on the first day and twice a day for the remaining 6 days, total 32.5 mg)
Study: 20595201
Drug: Nutritive solutions
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritive solutions (sucrose and NaCl)
Study: 20595201
Drug: Harmful solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harmful solutions (quinine and capsaicin)
Study: 18341178
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of 2 NRTI + 1 NNRTI (51%), 3 NRTI (45%), 2 NRTI + 1 PI (4%)
Study: 12067838
Drug: R-beta-hydroxybutyrate infusion
Normalized name: beta-citronellol, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-beta-hydroxybutyrate infusion
Study: 760753
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of free and conjugated paracetamol
Study: 30807834
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with low intensity laser (InGaAlP) and 0.005% methylene blue photosensitizer
Study: 25265472
Drug: peginterferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon beta‐1a 125 μg every 2 weeks
Study: 25265472
Drug: peginterferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon beta‐1a 125 μg every 4 weeks
Study: 9270664
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 2 g/kg
Study: 7525790
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (group A) excluding T1 tumours
Study: 17913583
Drug: No unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: No unfractionated heparin (no UFH)
Study: 14609161
Drug: Antibiotic-impregnated shunt
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic-impregnated shunt (AIS) system
Study: 22721632
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (IMN) 2 40-mg tablets
Study: 29046921
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg/day)
Study: 18307460
Drug: Rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (8 mg/day)
Study: 9704685
Drug: 1994 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1994 treatment (aspirin, ACE inhibitors, beta-blockers, nitrates, thrombolytic therapy, coronary angiography, PTCA, CABG)
Study: 8046740
Drug: Pentamidine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentamidine therapy
Study: 19794987
Drug: Antihistamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine (2 mL, 45.5 mg pheniramine maleate)
Study: 25199696
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (2 mL)
Study: 1704245
Drug: Self-help materials
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-help materials (audiotape and booklet) in addition to current treatment
Study: 1704245
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (current treatment only)
Study: 7286031
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of diacetolol 800 mg
Study: 26773246
Drug: Carbetocin (100mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (100mcg intravenous bolus)
Study: 26773246
Drug: Oxytocin (10IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (10IU intravenous bolus)
Study: 25157951
Drug: Extended-release oxycodone/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release oxycodone/acetaminophen (ER OC/APAP) 15/650 mg total dose, two tablets every 12 hours for ≤ 14 days
Study: 25157951
Drug: Extended-release oxycodone/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release oxycodone/acetaminophen (ER OC/APAP)
Study: 21811833
Drug: Pazopanib 400
Normalized name: PAZOPanib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 400 mg crushed tablet
Study: 21811833
Drug: Pazopanib 400
Normalized name: PAZOPanib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 400 mg oral suspension
Study: 21811833
Drug: Whole tablet
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole tablet administration
Study: 17467954
Drug: Prolactin-sparing anti-psychotics
Normalized name: prolactin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolactin-sparing anti-psychotics (e.g., olanzapine) with specific interventions (n=8)
Study: 17540667
Drug: Aprepitant 40
Normalized name: aprepitant 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 40 mg
Study: 12482109
Drug: Pulsed estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed estrogen therapy (Aerodiol)
Study: 2676648
Drug: Salsalate (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (1.5 g twice daily)
Study: 2676648
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg after evening meal)
Study: 23741991
Drug: Fosamprenavir/ritonavir 1400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosamprenavir/ritonavir 1400/100 mg with abacavir/lamivudine 600 mg/300 mg